VirginiaHB17242025 Regular SessionHouse

Prescription Drug Affordability Board; established, drug cost affordability review, report.

Sponsored By: Karrie K. Delaney (Democratic)

To Governor

Summary

Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between July 1, 2026, and January 1, 2029.The bill requires the Board to annually report its findings and recommendations to the General Assembly, beginning on December 31, 2026. Provisions of the bill apply to state-sponsored and state-regulated health plans and health programs and obligate such policies to limit drug payment amounts and reimbursements to an upper payment limit amount set by the Board, if applicable, following an affordability review. The bill specifies that Medicare Part D plans are not bound by such decisions of the Board.The bill also requires the nonprofit organization contracted by the Department of Health to provide prescription drug price transparency to provide the Board access to certain data reported by manufacturers. The bill has a delayed effective date of July 1, 2026.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & Cosponsors

Sponsor

  • Karrie K. Delaney

    Democratic • House

Cosponsors

There are no cosponsors for this bill.

Roll Call Votes

All Roll Calls

Yes: 284 • No: 148

House vote • 2/19/2025

Senate substitute agreed to by House

Yes: 52 • No: 45

Senate vote • 2/18/2025

Passed Senate with substitute

Yes: 26 • No: 14

Senate vote • 2/18/2025

Reconsideration of Senate passage agreed to by Senate

Yes: 40 • No: 0

Senate vote • 2/18/2025

Passed Senate with substitute

Yes: 24 • No: 16

Senate vote • 2/17/2025

Constitutional reading dispensed Block Vote (on 2nd reading)

Yes: 39 • No: 0

Senate vote • 2/14/2025

Reported from Finance and Appropriations with substitute

Yes: 10 • No: 4

Senate vote • 2/10/2025

Reported from Commerce and Labor and rereferred to Finance and Appropriations

Yes: 10 • No: 5

House vote • 1/31/2025

Read third time and passed House

Yes: 52 • No: 44

House vote • 1/27/2025

Reported from Appropriations

Yes: 14 • No: 8

House vote • 1/24/2025

Subcommittee recommends reporting

Yes: 5 • No: 2 • Other: 1

House vote • 1/14/2025

Reported from Labor and Commerce and referred to Appropriations

Yes: 12 • No: 10

Actions Timeline

  1. House sustained Governor's veto

    4/2/2025House
  2. Vetoed by Governor

    3/24/2025Governor
  3. Governor's Action Deadline 11:59 p.m., March 24, 2025

    3/11/2025Governor
  4. Enrolled Bill communicated to Governor on March 11, 2024

    3/11/2025House
  5. Signed by President

    3/10/2025Senate
  6. Fiscal Impact Statement from Department of Planning and Budget (HB1724)

    3/7/2025House
  7. Enrolled

    3/7/2025House
  8. Signed by Speaker

    3/7/2025House
  9. Fiscal Impact Statement from Department of Planning and Budget (HB1724)

    2/19/2025House
  10. Senate substitute agreed to by House (52-Y 45-N)

    2/19/2025House
  11. Passed Senate with substitute (26-Y 14-N)

    2/18/2025Senate
  12. Reconsideration of Senate passage agreed to by Senate

    2/18/2025Senate
  13. Passed Senate with substitute (24-Y 16-N)

    2/18/2025Senate
  14. Engrossed by Senate - committee substitute

    2/18/2025Senate
  15. Finance and Appropriations Substitute agreed to

    2/18/2025Senate
  16. Read third time

    2/18/2025Senate
  17. Reading of substitute waived

    2/18/2025Senate
  18. Constitutional reading dispensed Block Vote (on 2nd reading) (39-Y 0-N)

    2/17/2025Senate
  19. Passed by for the day

    2/17/2025Senate
  20. Rules suspended

    2/17/2025Senate
  21. Reported from Finance and Appropriations with substitute (10-Y 4-N)

    2/14/2025Senate
  22. Committee substitute printed 25107574D-S1

    2/14/2025Senate
  23. Reported from Commerce and Labor and rereferred to Finance and Appropriations (10-Y 5-N)

    2/10/2025Senate
  24. Referred to Committee on Commerce and Labor

    2/3/2025Senate
  25. Constitutional reading dispensed (on 1st reading)

    2/3/2025Senate

Bill Text

Related Bills

Back to State Legislation